ATAI Life Sciences
ATAI Life Sciences develops innovative mental health treatments that address significant unmet medical needs.
Business Model:
Revenue: $20.3M
Employees: 51-200
Rankings
Industries / Tags:
Detailed ATAI Life Sciences Information
Geographic Data
Address: Krausenstraße 9-10
City: Berlin
State: berlin
Zip: 10117
Country: DE
Financial Info
Stage:
Raised Last:
$0
Raised Total:$347M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
876,296Website Global Rank
41,122Website Monthly Traffic
Twitter Followers
Description
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Contact Phone:
Contact Email:
ATAI Life Sciences went public on 6/17/2021 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/17/2021
IPO Valuation:
$2B
Ticker Symbol:
ATAI
IPO Price:
$15/share
Amount Raised:
$225M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 3/2021 | IntelGenX | Post-IPO Debt | 2M |
| 2/2022 | IntelGenX | Post-IPO Debt | 3M |
| 4/2019 | Innoplexus | Series C | - |
| 3/2021 | IntelGenX | Post-IPO Equity | 12.3M |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 1/2023 | IntelGenX | Post-IPO Debt | 3M |
| 2/2022 | IntelGenX | Post-IPO Debt | 0 |
| 3/2021 | IntelGenX | Post-IPO Equity | 0 |
| 3/2021 | IntelGenX | Post-IPO Debt | 0 |
| 4/2020 | COMPASS Pathways | Series B | 0 |
| 4/2019 | Innoplexus | Series C | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
